A Dose-Escalating Pilot Study of Sterically Stabilized, Pegylated Liposomal Doxorubicin (Lipo-Dox®) in Patients with Metastatic Breast Cancer

Cancer Investigation

Volumn 21, Issue 6, 2003, Pages 837-847

  Chao, Ta Chung ^a   Wang, Wei Shu ^a   Yen, Chueh Chuan ^a   Chiou, Tzeon Jye ^a   Liu, Jin Hwang ^a   Chen, Po Min ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Doxorubicin; Liposome; Metastatic breast cancer

Indexed keywords

CYTOTOXIC AGENT; DOXORUBICIN; DOXORUBICIN DERIVATIVE; LIPO DOX; LIPOSOME; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DESQUAMATION; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; LIVER TOXICITY; METASTASIS; NAUSEA; NEUTROPENIA; PILOT STUDY; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 0347988148     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120025086     Document Type: Article

References (22)

1. Hortobagyi, G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54 (suppl 4), 1-7.
2. Aapro, M.S. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings. Semin. Oncol. 1999, 26 (suppl 3), 17-21.
3. Tan, A.R.; Swain, S.M. Adjuvant chemotherapy for breast cancer: an update. Semin. Oncol. 2001, 28 (4), 359-376.
4. Allen, T.M. Liposomes. Opportunities in drug delivery. Drugs 1997, 54 (suppl 4), 8-14.
5. Gabizon, A.; Martin, F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 1997, 54 (suppl 4), 15-21.
6. Muggia, F.M. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs 1997, 54 (suppl 4), 22-29.
7. Alberts, D.S.; Garcia, D.J. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997, 54 (suppl 4), 30-35.
8. Gabizon, A.; Goren, D.; Horowitz, A.T.; Tzemach, D.; Lossos, A.; Siegal, T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev. 1997, 24, 337-344.
9. Drummond, D.C.; Meyer, O.; Hong, K.; Kirpotin, D.B.; Papahadjopoulos, D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51 (4), 691-743.
10. Ranson, M.R.; Cheeseman, S.; White, S.; Margison, J. Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit. Rev. Oncol. Hematol. 2001, 37, 115-120.
11. Gabizon, A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19 (4), 424-436.
12. Sparano, J.A.; Winer, E.P. Liposomal anthracyclines for breast cancer. Semin. Oncol. 2001, 28 (4), 32-40 (suppl 12).
13. Ranson, M.R.; Carmichael, J.; O'Byrne, K.; Stewart, S.; Smith, D.; Howell, A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J. Clin. Oncol. 1997, 15 (10), 3185-3191.
14. Hong, R.L.; Tseng, Y.L. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors. Cancer 2001, 91 (9), 1826-1833.
15. Gianni, L. Anthracycline resistance: the problem and its current definition. Semin. Oncol. 1997, 24 (4), 11-17 (suppl 10).
16. Uziely, B.; Jeffers, S.; Isacson, R.; Kutsch, K.; Wei-Tsao, D.; Yehoshua, Z.; Libson, E.; Muggia, F.M.; Babizon, A. Liposomal doxorubicin: anti-tumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 1995, 13 (7), 1777-1785.
17. Lyass, O.; Uziely, B.; Ben-Yosef, R.; Tzemach, D.; Heshing, N.I.; Lotem, M.; Brufman, G.; Gabizon, A. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (doxil) in metastatic breast carcinoma. Cancer 2000, 89 (5), 1037-1047.
18. Smith, F.P.; Barr, F.; Hendricks, C.; Burrell, L. Phase II study of DOXIL (pegylated liposomal doxorubicin) in doxorubicin-resistant, metastatic breast cancer. Am. Soc. Clin. Oncol. 1999, 18, abstract 524.
19. Cowens, J.W.; Creaven, P.J.; Greco, W.R.; Brenner, D.E.; Tung, Y.; Ostro, M.; Pilkiewicz, R.; Ginsberg, R.; Petrelli, N. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. 1993, 53, 2796-2802.
20. 2. Ann. Oncol. 2000, 11, 1029-1033.
21. Mustafa, M.H. Decreased risk of cardiotoxicity with long-term use of doxil/caelyx at high lifetime cumulative doses in patients with AIDS-related Kaposi's sarcoma (KS). Am. Soc. Clin. Oncol. 2001, 20, abstract 2915.
22. Harris, L.; Batist, G.; Belt, R.; Rovira, D.; Navari, R.; Azamia, N.; Welles, L.; Winer, E.; for the TLC D-99 Study Group. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast cacinoma. Cancer 2002, 94 (1), 25-36.